Aerius

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

desloratadine

Available from:

N.V. Organon

ATC code:

R06AX27

INN (International Name):

desloratadine

Therapeutic group:

Antihistamines for systemic use,

Therapeutic area:

Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal

Therapeutic indications:

Aerius is indicated for the relief of symptoms associated with:allergic rhinitis;urticaria.

Product summary:

Revision: 50

Authorization status:

Authorised

Authorization date:

2001-01-15

Patient Information leaflet

                                30
B. PACKAGE LEAFLET
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
AERIUS 5 MG FILM-COATED TABLETS
desloratadine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Aerius is and what it is used for
2.
What you need to know before you take Aerius
3.
How to take Aerius
4.
Possible side effects
5.
How to store Aerius
6.
Contents of the pack and other information
1.
WHAT AERIUS IS AND WHAT IT IS USED FOR
WHAT AERIUS IS
Aerius contains desloratadine which is an antihistamine.
HOW AERIUS WORKS
Aerius is an antiallergy medicine that does not make you drowsy. It
helps control your allergic
reaction and its symptoms.
WHEN AERIUS SHOULD BE USED
Aerius relieves symptoms associated with allergic rhinitis
(inflammation of the nasal passages caused
by an allergy, for example, hay fever or allergy to dust mites) in
adults and adolescents 12 years of age
and older. These symptoms include sneezing, runny or itchy nose, itchy
palate, and itchy, red or
watery eyes.
Aerius is also used to relieve the symptoms associated with urticaria
(a skin condition caused by an
allergy). These symptoms include itching and hives.
Relief of these symptoms lasts a full day and helps you to resume your
normal daily activities and
sleep.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AERIUS
DO NOT TAKE AERIUS
-
if you are allergic to desloratadine, or any of the other ingredients
of this medicine (listed in
section 6) or to loratadine.
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before taking Aerius:
-

                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Aerius 5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5 mg desloratadine.
Excipient(s) with known effect
This medicinal product contains lactose (see section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablets
Light blue, round and embossed film-coated tablets with elongated
letters “S” and “P” on one side and
plain on the other. The diameter of the film-coated tablet is 6.5 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Aerius is indicated in adults and adolescents aged 12 years and older
for the relief of symptoms
associated with:
-
allergic rhinitis (see section 5.1)
-
urticaria (see section 5.1)
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults and adolescents (12 years of age and over) _
The recommended dose of Aerius is one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4
days per week or for less than
4 weeks) should be managed in accordance with the evaluation of
patient’s disease history and the
treatment could be discontinued after symptoms are resolved and
reinitiated upon their reappearance.
In persistent allergic rhinitis (presence of symptoms for 4 days or
more per week and for more than
4 weeks), continued treatment may be proposed to the patients during
the allergen exposure periods.
_ _
_Paediatric population _
There is limited clinical trial efficacy experience with the use of
desloratadine in adolescents
12 through 17 years of age (see sections 4.8 and 5.1).
The safety and efficacy of Aerius 5 mg film-coated tablets in children
below the age of 12 years have
not been established.
Method of administration
Oral use.
The dose can be taken with or without food.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance, to any of the excipients
listed in section 6.1, or to loratadine.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Renal function impairment
In th
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 02-08-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 02-08-2023
Public Assessment Report Public Assessment Report Bulgarian 09-06-2015
Patient Information leaflet Patient Information leaflet Spanish 02-08-2023
Public Assessment Report Public Assessment Report Spanish 09-06-2015
Patient Information leaflet Patient Information leaflet Czech 02-08-2023
Public Assessment Report Public Assessment Report Czech 09-06-2015
Patient Information leaflet Patient Information leaflet Danish 02-08-2023
Public Assessment Report Public Assessment Report Danish 09-06-2015
Patient Information leaflet Patient Information leaflet German 02-08-2023
Public Assessment Report Public Assessment Report German 09-06-2015
Patient Information leaflet Patient Information leaflet Estonian 02-08-2023
Public Assessment Report Public Assessment Report Estonian 09-06-2015
Patient Information leaflet Patient Information leaflet Greek 02-08-2023
Public Assessment Report Public Assessment Report Greek 09-06-2015
Patient Information leaflet Patient Information leaflet French 02-08-2023
Public Assessment Report Public Assessment Report French 09-06-2015
Patient Information leaflet Patient Information leaflet Italian 02-08-2023
Public Assessment Report Public Assessment Report Italian 09-06-2015
Patient Information leaflet Patient Information leaflet Latvian 02-08-2023
Public Assessment Report Public Assessment Report Latvian 09-06-2015
Patient Information leaflet Patient Information leaflet Lithuanian 02-08-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 02-08-2023
Public Assessment Report Public Assessment Report Lithuanian 09-06-2015
Patient Information leaflet Patient Information leaflet Hungarian 02-08-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 02-08-2023
Public Assessment Report Public Assessment Report Hungarian 09-06-2015
Patient Information leaflet Patient Information leaflet Maltese 02-08-2023
Public Assessment Report Public Assessment Report Maltese 09-06-2015
Patient Information leaflet Patient Information leaflet Dutch 02-08-2023
Public Assessment Report Public Assessment Report Dutch 09-06-2015
Patient Information leaflet Patient Information leaflet Polish 02-08-2023
Public Assessment Report Public Assessment Report Polish 09-06-2015
Patient Information leaflet Patient Information leaflet Portuguese 02-08-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 02-08-2023
Public Assessment Report Public Assessment Report Portuguese 09-06-2015
Patient Information leaflet Patient Information leaflet Romanian 02-08-2023
Public Assessment Report Public Assessment Report Romanian 09-06-2015
Patient Information leaflet Patient Information leaflet Slovak 02-08-2023
Public Assessment Report Public Assessment Report Slovak 09-06-2015
Patient Information leaflet Patient Information leaflet Slovenian 02-08-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 02-08-2023
Public Assessment Report Public Assessment Report Slovenian 09-06-2015
Patient Information leaflet Patient Information leaflet Finnish 02-08-2023
Public Assessment Report Public Assessment Report Finnish 09-06-2015
Patient Information leaflet Patient Information leaflet Swedish 02-08-2023
Public Assessment Report Public Assessment Report Swedish 09-06-2015
Patient Information leaflet Patient Information leaflet Norwegian 02-08-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 02-08-2023
Patient Information leaflet Patient Information leaflet Icelandic 02-08-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 02-08-2023
Patient Information leaflet Patient Information leaflet Croatian 02-08-2023
Public Assessment Report Public Assessment Report Croatian 09-06-2015

Search alerts related to this product

View documents history